Half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV ...

A new study details how a nasal spray formulated by investigators from Brigham and Women's Hospital may work to protect ...

KT-621 has the potential to provide dupilumab-like activity with an oral small molecule profile for TH2 driven allergic and atopic disease KT-621 demonstrated strong degradation of STAT6 in human ...

Psychedelics biotech company Enveric Biosciences (NASDAQ: ENVB) has presented research highlighting the company's lead ...

Study explores the potential to repurpose neuroactive drugs, originally approved for neurological disorders, for the ...

OncoC4 is taking AcroImmune—and its in-house clinical manufacturing capabilities—under its wing in an all-stock merger. | ...

Cassava Sciences' stock rose 9% after completing a trial of its Alzheimer's drug, Simufilam, but the company's future remains ...

Voyager Therapeutics (VYGR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

BioAge Labs (BIOA), which is developing a drug to augment popular weight-loss medications such as Wegovy and Zepbound, has upsized its proposed IPO. Read more here.

The transfer of knowledge from animal models to humans is essential for unraveling disease mechanisms and developing precise ...

The data were presented at the Keystone Symposium Targeting Dry Age-related Macular Degeneration: Pathophysiology and ...

Huadong Medicine Co. Ltd. recently revealed data from in vitro and preclinical studies performed to evaluate the efficacy and pharmacokinetic, safety and tolerability profiles of a dual glucagon-like ...